08.09.21
Berry Global is establishing a second manufacturing facility and global healthcare center of excellence in Bangalore, India. Planned for development near Berry’s existing Bangalore operation, the new facility will enable the company to extend its R&D expertise and scale up production in several key healthcare sectors: ophthalmic, nasal pumps, inhalation, and injectable administrations. The increased capacity will also enhance supply in India and throughout South Asia, addressing some of the fastest growing healthcare market geographies.
“Investing in our global healthcare business in Bangalore is a significant step in supporting our pharmaceutical, over-the-counter, and medical device customers aligned to forecasted market needs,” remarks Tom Salmon, Berry Global's Chairman and CEO. "During the pandemic, we've learned that strategically placed facilities across the world provide efficient localized support for customers of any size. We believe this investment significantly benefits the India and South Asia patient populations."
The Berry Healthcare site addition in Bangalore offers a vast wealth of technical experience and a regular pipeline of future talent through its network of universities. Building on the company's established expertise in healthcare will allow the continued development of innovative solutions for existing and new applications while improving the patient experience for medicine administration and maintaining the highest functionality in areas such as ease of use, dosage control, and effective medicine protection.
Among its development work, Berry will continue to focus on its current leadership in inhalation devices, including models with digital capabilities and the next generation of injectable devices. Another central area of activity will be introducing innovations in nasal and ophthalmic spray pumps and healthcare packaging for various products.
Alongside precision high-quality manufacturing equipment, the new facility will also house a dedicated R&D Center of Excellence. In addition to ensuring the dosing and administering of medicines are both easy and comfortable for the user, another critical design criterion will be to support customers' sustainability goals, with the existing Bangalore facility already International Sustainability and Carbon Certificate (ISCC) Plus accredited. This allows Berry to sell ISCC certified packaging and plastic components that contribute to a circular economy approach based on advanced recycling and mass balance. The mass balance approach makes it possible to track the amount and sustainability characteristics of circular and/or bio-based content in the value chain and attribute it based on verifiable bookkeeping, according to the ISCC organization.
Construction of the new facility is expected to begin later this year, with the site validated and ready for production by the summer of 2023.
The existing Berry Healthcare facility in Bangalore was opened in 2009. It is the market leader in ophthalmic and child-resistant closures in India and also produces the Risdrop user-independent eye drop, winner of the Best Innovation Award at CPhI China.
“Investing in our global healthcare business in Bangalore is a significant step in supporting our pharmaceutical, over-the-counter, and medical device customers aligned to forecasted market needs,” remarks Tom Salmon, Berry Global's Chairman and CEO. "During the pandemic, we've learned that strategically placed facilities across the world provide efficient localized support for customers of any size. We believe this investment significantly benefits the India and South Asia patient populations."
The Berry Healthcare site addition in Bangalore offers a vast wealth of technical experience and a regular pipeline of future talent through its network of universities. Building on the company's established expertise in healthcare will allow the continued development of innovative solutions for existing and new applications while improving the patient experience for medicine administration and maintaining the highest functionality in areas such as ease of use, dosage control, and effective medicine protection.
Among its development work, Berry will continue to focus on its current leadership in inhalation devices, including models with digital capabilities and the next generation of injectable devices. Another central area of activity will be introducing innovations in nasal and ophthalmic spray pumps and healthcare packaging for various products.
Alongside precision high-quality manufacturing equipment, the new facility will also house a dedicated R&D Center of Excellence. In addition to ensuring the dosing and administering of medicines are both easy and comfortable for the user, another critical design criterion will be to support customers' sustainability goals, with the existing Bangalore facility already International Sustainability and Carbon Certificate (ISCC) Plus accredited. This allows Berry to sell ISCC certified packaging and plastic components that contribute to a circular economy approach based on advanced recycling and mass balance. The mass balance approach makes it possible to track the amount and sustainability characteristics of circular and/or bio-based content in the value chain and attribute it based on verifiable bookkeeping, according to the ISCC organization.
Construction of the new facility is expected to begin later this year, with the site validated and ready for production by the summer of 2023.
The existing Berry Healthcare facility in Bangalore was opened in 2009. It is the market leader in ophthalmic and child-resistant closures in India and also produces the Risdrop user-independent eye drop, winner of the Best Innovation Award at CPhI China.
